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Simple Summary: A dysregulated metabolism is a hallmark of cancer. Once understood, tumor
metabolic reprogramming can lead to targetable vulnerabilities, spurring the development of novel
treatment strategies. Beyond the common observation that tumors rely heavily on glucose, building
evidence indicates that a subset of tumors use lipids to maintain their proliferative or metastatic
phenotype. This study developed an intra-vital microscopy method to quantify lipid uptake in
breast cancer murine models using a fluorescently labeled palmitate molecule, Bodipy FL c16. This
work highlights optical imaging’s ability to both measure metabolic endpoints non-destructively and
repeatedly, as well as inform small animal metabolic phenotyping beyond in vivo optical imaging of
breast cancer alone.
Abstract: Targeting a tumor’s metabolic dependencies is a clinically actionable therapeutic approach;
however, identifying subtypes of tumors likely to respond remains difficult. The use of lipids as
a nutrient source is of particular importance, especially in breast cancer. Imaging techniques offer
the opportunity to quantify nutrient use in preclinical tumor models to guide development of new
drugs that restrict uptake or utilization of these nutrients. We describe a fast and dynamic approach
to image fatty acid uptake in vivo and demonstrate its relevance to study both tumor metabolic
reprogramming directly, as well as the effectiveness of drugs targeting lipid metabolism. Specifically,
we developed a quantitative optical approach to spatially and longitudinally map the kinetics of
long-chain fatty acid uptake in in vivo murine models of breast cancer using a fluorescently labeled
palmitate molecule, Bodipy FL c16. We chose intra-vital microscopy of mammary tumor windows to
validate our approach in two orthotopic breast cancer models: a MYC-overexpressing, transgenic,
triple-negative breast cancer (TNBC) model and a murine model of the 4T1 family. Following
injection, Bodipy FL c16 fluorescence increased and reached its maximum after approximately 30 min,
with the signal remaining stable during the 30–80 min post-injection period. We used the fluorescence
at 60 min (Bodipy60), the mid-point in the plateau region, as a summary parameter to quantify
Bodipy FL c16 fluorescence in subsequent experiments. Using our imaging platform, we observed
a two- to four-fold decrease in fatty acid uptake in response to the downregulation of the MYC
oncogene, consistent with findings from in vitro metabolic assays. In contrast, our imaging studies
report an increase in fatty acid uptake with tumor aggressiveness (6NR, 4T07, and 4T1), and uptake
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was significantly decreased after treatment with a fatty acid transport inhibitor, perphenazine, in both
normal mammary pads and in the most aggressive 4T1 tumor model. Our approach fills an important
gap between in vitro assays providing rich metabolic information at static time points and imaging
approaches visualizing metabolism in whole organs at a reduced resolution.
Keywords: fluorescence microscopy; fatty acid uptake; metabolism; breast murine tumor lines;
metastatic potential; oncogene addition
1. Introduction
Cellular metabolism involves a vital network of pathways for homeostasis, growth,
and survival. Alterations in these pathways are key features of a variety of diseases and
conditions, such as diabetes, obesity, and cancer [1–3]. In cancer, oncogene activation or
loss of tumor suppressors contributes to dysregulated metabolism, causing altered nutrient
requirements compared to normal cells [4,5]. Aerobic glycolysis is frequently upregulated
in tumor cells, and fluorodeoxyglucose-positron emission tomography (FDG-PET) can
measure glucose uptake to stage a patient’s cancer, assess response to therapy, and evaluate
progression [6]. Yet, a steadily growing number of studies suggest that tumors rely on
additional energetic sources [7], including glutamine, amino acids, and lipids [8].
The use of lipids as a nutrient source is of particular importance in breast cancer, as an
increase in lipid droplet formation is associated with increased tumor aggressiveness [9,10].
Adipocytes surround invasive breast cancers and serve as professional lipid storing cells,
providing a readily available carbon source [11–14]. Adipocytes surrounding aggressive
primary tumors show a loss of lipid content and increased IL-6 expression [15], a key
inflammatory cytokine previously implicated in migration and invasion of breast cancer
cells [16]. Further, fatty acids are often the preferential carbon source in drug-resistant and
residual cancer [17–19].
Novel methods to quantify the use of new energetic sources, including lipids, in pre-
clinical models will aid in the development of drugs to restrict uptake or utilization of these
nutrients. In vitro and ex vivo assays, like the Seahorse Assay and metabolomics, quantify
multiple metabolic endpoints; however, both are restricted to single, static time points
and sacrifice spatial information. In vivo imaging technologies have the potential to allow
for repeated measurements of single or multiple metabolic endpoint(s) for dynamically
studying metabolic reprogramming. Further, imaging-based techniques could be used
for studying the effectiveness of metabolically targeted therapeutics within the tumor
microenvironment.
The ability to directly study fatty acid uptake within the context of an intact tumor-
bearing animal is critical for evaluating novel therapeutics that antagonize lipid pathways
or use lipids as an energy source. The most common in vivo metabolic imaging modality
currently used for metabolic imaging is FDG-PET to measure glucose uptake with a radio-
labeled glucose tracer [20]. Previous studies outside of breast cancer have validated the
use of an additional radio-labeled PET tracer, 18F-fluoro-6-thia-heptadecanoic acid (18F-
FTHA), for in vivo fatty acid uptake measurements for myocardium imaging [21], and,
more recently, for prostate cancer [22] and melanoma [23]. Though metabolic imaging
through PET has proved valuable, especially in the clinic, its millimeter-scale resolution
prevents capture of tumor heterogeneity [24,25], which tend to be under 1 cm in diameter.
Further, PET cannot be used to measure multiple endpoints at the same time.
Optical imaging allows for the temporal mapping of fatty acid uptake, as seen in
PET imaging, but at a high enough resolution for spatial mapping of preclinical tumors,
providing complementary metabolic information to existing techniques. Additionally,
optical approaches have the capacity to image several endogenous sources of contrast [26]
and can be coupled with appropriate exogenous indicators to provide functional and
molecular information. In either case, high-resolution imaging of both in vitro and in vivo
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models of cancer can be performed [27–33]. Bodipy FL c16 (4,4-Difluoro-5,7-Dimethyl-
4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid) is an exogenous indicator that has
been successfully and extensively used in vitro to measure fatty acid uptake and, by ex-
tension, fatty acid (β) oxidation activity [34]. Bodipy FL c16 is comprised of a fluorophore
and a 16-carbon long-chain fatty acid (palmitic acid), the most common saturated fat in
animals [35]. Though Bodipy FL c16 has also been administered in vivo and quantified ex
vivo by flow cytometry [36], optical in vivo imaging of Bodipy FL c16 to enable both longi-
tudinal and spatial mapping of in vivo fatty acid uptake visualization has not previously
been performed.
Here, we adapted and rigorously validated the fluorescent palmitate analog, Bodipy
FL c16, for in vivo imaging of fatty acid uptake. For this study, we specifically developed
our injection strategy and summary time points using intra-vital microscopy of a mammary
window breast tumor model so as to visualize local changes in fatty acid uptake in the
precise orthotopic region where the tumor was implanted; however, our approach can
be adapted to optical imaging using a variety of technologies that differ in terms of
depth of penetration, resolution, and field of view. Two different endpoints were used in
our study: a summary parameter for overall Bodipy FL c16 uptake and a heterogeneity
parameter providing spatial information. We performed intravital Bodipy FL c16 imaging
of two syngeneic breast cancer models: the MMTV-Tet-O-MYC conditional model of triple
negative breast cancer (TNBC) (MTB-TOM) [37] and the transplanTable 4T1, 4T07, and
67NR tumors in a mammary carcinoma model [38]. In the MTB-TOM model, Bodipy FL
c16 fluorescence decreased following downregulation of MYC. Conversely, in animals
with orthotopic transplantation of the 4T1 family of tumors [39], fatty acid uptake and
heterogeneity increased with tumor metastatic potential. In this same 4T1 family orthotopic
model, Bodipy FL c16 fluorescence was significantly decreased with the addition of a small
molecule inhibitor, perphenazine, an inhibitor of fatty acid uptake [40], exemplifying
another use of our approach: monitoring metabolic changes following therapy. In vivo
optical imaging of fatty acid uptake with Bodipy FL c16 bridges an important gap in the
field of cancer metabolism between in vitro-only single-time point assays, and in vivo PET
imaging. Further, these methodology studies serve as the foundation upon which imaging
of fatty acid uptake can be adapted to different types of optical imaging systems.
2. Results
2.1. In Vivo Imaging of Fluorescently Labeled Fatty Acids in Mammary Window Chambers
Due to their destructive nature, existing technologies that measure long-chain fatty
acid uptake within tumor tissues are often limited in their ability to temporally study
a single tumor [41,42]. Fluorescence imaging provides an opportunity to non-invasively
study the dynamics of fatty acid metabolism over time, moving past the limitations of
a static snapshot of fatty acid levels. To capture longitudinal fatty acid uptake and model
a patient treatment cascade, we designed an imaging strategy using Bodipy FL c16. Bodipy
FL c16, a commercially available fluorescent palmitate analog, consists of a 16-carbon
long-chain fatty acid molecule linked to a Bodipy dye (Figure 1A). Bodipy FL c16 can be
delivered systemically via tail vein injection (Figure 1B). Importantly, Bodipy FL c16 only
enters cells via long-chain fatty acid transport proteins like normal fatty acids and not
through simple cell membrane diffusion [34], making Bodipy FL c16 fluorescence a‘reliable
indicator of true fatty acid transport. Once the probe is taken up into the target cell,
it accumulates in the cytoplasm, providing an indicator of how rapidly cells are importing
fatty acids. Because the 16th carbon of the palmitate is fluorescently labeled, immediate
degradation of the Bodipy dye during fatty acid oxidation (β-oxidation) is prevented.
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Figure 1. Methods for imaging palmitate uptake through Bodipy FL c16 in mammary window chambers using intravital
fluorescence microscopy. (A) Schematic of fluorescently labeled palmitate, a 16-carbon-chain fatty acid (Bodipy FL c16).
The fluorescent label is marked with a green circle. (B) Prior to imaging, a titanium mammary window chamber is implanted
over the 4th right mammary fat pad of the mouse. 100 µL of 200 µM Bodipy FL c16 is administered via the tail vein for each
imaging session. (C) Fluorescent probe accumulation into the mammary window chamber is measured by exciting the
probe at 488 nm and collecting the emitted signal at 515 nm. (D) Timeline indicating the longitudinal imaging time course
for each imaging session.
For intravital imaging, a 12 mm diameter titanium window was implanted over the
tumor in the 4th mammary gland of each female mouse. The field of view within the
window was excited at 488 ± 5 nm and collected at 515 ± 3.5 nm emission for fluorescence
imaging (Figure 1C). To account for endogenous fluorescence differences between tumors,
a background and dark image were collected and subtracted from each post-injection
image to ensure all reported signals were only due to Bodipy FL c16. Each mouse was
imaged sequentially for a total of 80 min post-Bodipy FL c16 injection (Figure 1D).
2.2. Bodipy FL c16 Uptake Differentiates MYC Oncogene Signaling in Tumors
Previous studies found that tumors that overexpress the MYC oncogene, such as
receptor triple-negative breast cancers (TNBC), have increased uptake of stable isotope-
labeled fatty acids in a MTB-TOM model [43]. We chose to assess our optical imaging
technology using the same model, where MYC expression is activated by doxycycline
(dox) [37,43]. We used a concentration of doxycycline (10 ng/mL) that allowed for the
control of MYC expression without changes to fatty acid uptake levels, as shown in
Figure S1, based on previous studies showing that doxycycline and other tetracyclines
inhibit mitochondrial activity at and above the µg/mL level [44–46]. However, at the
ng/mL level, the primary effect of doxycycline is in gene regulation [47–49]. Modulation
of MYC through dox allows for temporal assessment of metabolism as tumors grow while
on dox and regress after dox removal. To image Bodipy FL c16 uptake during murine
tumor growth and r gr ssion, 100 µL of 200 µM Bodipy FL c16 was injected via the tail vein
and fluorescence microscopy images (field of view: 2.1 mm × 1.6 mm) of the mammary
tumor were captu d over a span of 80 mi post-injection while mice wer receiving ad
libitum dox (tumor growth w th MYC-on) or fou days aft r withdrawal of dox (early
tumor regression with MYC-off [50]).
Figure 2A shows representative pre- and post-injection images from growing and
regressing tumors, depicting the delivery kinetics of Bodipy FL c16 across the window
chamber following Bodipy FL c16 systemic delivery in the MYC-on (+dox) and MYC-off
tumors (−dox for 4 days). Fluorescence images are quantified via Bodipy FL c16 uptake
curves in Figure 2B. Following MYC inhibition for 4 days, tumors regressed in size by
~2-fold (320 vs. 173 mm3; p < 0.05), and tumors’ Bodipy FL c16 uptake was significantly
decreased, ~3-fold less at peak (Figure 2B; p < 0.05) compared to MYC-on tumors.
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Figure 2. Bodipy FL c16 fluorescence peaks and then plateaus 30 in post-injection and YC downregulation ( YC-off)
results in a significant decrease in Bodipy FL c16 uptake. Bodipy FL c16 uptake was measured in mammary tumors
overexpressing the oncogene MYC (+dox) and mammary tumors in which MYC was downregulated (−dox). (A) Represen-
tative images of Bodipy FL c16 fluorescence images over 80 min in a mammary tumor with MYC-on (+dox) and MYC-off
(four days after dox was removed). Baseline images were acquired prior to Bodipy FL c16 injection and its average was
subtracted from the images acquired after Bodipy FL c16 administration. Scale bar = 200 µm. (B) Average Bodipy FL c16
kinetic curves for the MYC-on (+dox) and MYC-off (−dox) groups. (C) For a given mouse, the kinetic curve was normalized
to its peak B dipy FL c16 fluorescence and normalized kinetics were t n averaged for each gro p. Error bars represent
standard error (sample size: MYC-on = 4 mi , MYC-off = 4 mice). The mid-point of the plat au, 60 min, was used to
represent the Bodipy FL c16 (Bodipy60) fluorescence for subsequent analyses. Statistical differences in mean kinetic curves
were determined using a two-way analysis of variance (ANOVA) test.
To illustrate that the delivery kinetics of Bodipy FL c16 were independent of Bodipy
FL c16 uptake level, each mammary window’s kinetic curve in Figure 2B was normalized
to its maximum fluorescence intensity. Normalizing each kinetic curve to its respective
maximum fluorescence (Figure 2C) shows that, in both the MYC-on and MYC-off groups,
Bodipy FL c16 accumulates into the window for approximately 30 min and remains stable
for 30–80 min post-injection. We used the fluorescence at 60 min (Bodipy60), the mid-point
in the plateau region, as a summary parameter to quantify Bodipy FL c16 fluorescence
in subsequent experiments. Thus, MYC-dependent uptake of long-chain fatty acids can
be visualized with Bodipy FL c16 in accordance with previously reported stable isotope
uptake studies in this model [43].
2.3. MYC Overexpression Corresponds to Increased Fatty Acid Transport Protein Expression
Long-chain fatty acid (LCFA) uptake and trafficking within cells can be mediated by
multiple receptors and carriers. Therefore, the increased Bodipy FL c16 uptake observed in
MYC-on tumors may be mediated by multiple effector molecules. To evaluate which effec-
tor molecules are important for fatty acid uptake in MYC-driven tumors, we characterized
the effect of MYC expression on cell surface transport proteins which have been reported
to mediate LCFA uptake (Figure S2A). CD36 and the SLC27 gene family responsible for
creating the fatty acid transport proteins (FATPs) have been shown to be critical in both the
Cancers 2021, 13, 148 6 of 20
uptake and activation of long-chain fatty acids for fatty acid oxidation (β-oxidation) [51,52].
We analyzed RNA sequencing data of MTB-TOM tumors [53] to investigate how regulating
MYC expression affects CD36 and FATP-family expression. When MYC was turned off
through dox withdrawal, at an RNA level, Slc27a3 was the mRNA sequence in the family
that decreased in expression, though not significantly (Supplementary Figure S2A). How-
ever, MYC may indirectly regulate protein abundance by altering ribosome biogenesis and
translation pathways [54–56]. The mRNA Slc27a3 sequence specifically codes for FATP3;
thus, we examined FATP3 protein expression in multiple MTB-TOM tumors. We found
concomitant decreases in MYC and FATP3 protein expression when dox is removed during
early tumor regression (Figure 3A; full blot, Supplementary Figure S2B). FATP3 protein ex-
pression was diminished by ~75% with the removal of dox (MYC-off) (Figure 3B; p < 0.05).
While it is possible that multiple mechanisms contribute to increased Bodipy FL c16 uptake
in MYC-on tumors, which are beyond the scope of the present study, we have identified at
least one FATP-family member, FATP3, whose expression is correlated to MYC in a model
of TNBC.
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With the importance of fatty acids in these MYC-on tumors established, we next ex-
plored how our method can longitudinally track metabolic changes in each animal fol-
lowing MYC downregulation. Longitudinal imaging was performed by imaging Bodipy 
FL c16 uptake in animals at baseline with MYC-on (+dox) and after MYC was turned off 
for four days (−dox for 4 days) (Figure 4A). Background images of the window chambers 
prior to the MYC-off imaging confirmed that Bodipy FL c16 had degraded, metabolized, 
or diffused out following the initial imaging session. We saw a significant decrease in av-
erage Bodipy60 fluorescence for MYC-off tumors compared to MYC-on tumors (p < 0.05) 
using a Wilcoxon signed-rank test (Figure 4B). Notably, we observed inter-tumoral heter-
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Figure 3. Loss of MYC expression results in decreased fatty acid transport protein 3 FATP3. (A) Western blots of FATP3 and
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2.4. Longitudinal Imaging Reveals odulation of MYC Expression Changes itochondrial
Metabolism
With the importance of fatty acids i these MYC-on tumors established, we next
explored how our method can longitudina ly tr ck metabolic changes in each animal
following MYC dow regulation. Longitudinal imaging was performed by imaging Bodipy
FL c16 uptake in animals a baseline with MYC-on (+dox) and after MYC was turned off for
four days (−dox for 4 days) (Figure 4A). Background images of the window chambers prior
to the MYC-off imaging confirmed that Bodipy FL c16 ha degraded, metabolized, or dif-
fused out following the initial imaging session. We saw significant decrease in average
Bodipy60 fluorescence for MYC- ff tu ors compared t MYC- n tumors (p < 0.05) using
a Wilcoxon signed-rank test (Figure 4B). Notably, we observed inter-tumoral heterogeneity
in lipid accumulation but nevertheless saw each mouse’s individual decrease in Bodipy60
following MYC-downregulation (dox withdrawal). Additionally, probability density func-
tions (PDFs), as shown in Figure 4C, were used to quantify the relative frequency of any
given pixel intensity across all animals within an experimental group to see if inter-tumor
heterogeneity masked changes in Bodipy FL c16 uptake. The PDF of MYC-off (−dox) is
significantly left-shifted relative to the MYC-on (+dox) group by Kolmogorov–Smirnov
(KS) testing (p < 0.05), signifying a decrease in the overall fluorescence (fatty acid uptake)
in the tissue regardless of inter-tumor heterogeneity.
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LCFAs serve as an important carbon source for oxidative phosphorylation after being
broken down through β-oxidation in MYC-on tumors [43,57]; therefore, understanding
how decreased availability of fatty acids through the reduction in MYC expression may
affect oxidative phosphorylation would permit for dynamic in vivo assessment of tumor
overall metabolic reprogramming. Previously, our group has established a method to
optically measure oxidative phosphorylation in vivo in preclinical models via tetramethyl-
rhodamine ethyl ester perchlorate (TMRE) [33]. This cationic molecule accumulates in
proportion to the mitochondrial membrane potential [58], which serves as a surrogate
for oxidative phosphorylation rates (i.e., increased mitochondrial membrane potential
correlates with increased levels of oxidative phosphorylation). Due to the unknown optical,
biological, or chemical crosstalk between Bodipy FL c16 and TMRE probes, a separate
cohort of mice was used to investigate TMRE uptake in MYC-on and MYC-off tumors.
Specifically, 100 µL of 75 µM TMRE was injected via the tail vein and fluorescence im-
ages were captured from the mammary window over a span of 60 min according to our
previously validated methods [33]. We observed TMRE60 (TMRE fluorescence 60 min post-
injection) images for MYC-on and MYC-off breast tumors (Figure 4D). Roughly a 3-fold
decrease in TMRE60 fluorescence was observed following four days of MYC downregu-
lation (Figure 4E). Additionally, the distribution of TMRE60 fluorescence shifted left in
MYC-off (−dox) tumors relative to MYC-on (+dox) tumors, as shown by the PDFs in
Figure 4F, indicating a decrease in oxidative phosphorylation. Here, we demonstrate the
dynamic assessment of both LCFA uptake and oxidative phosphorylation in MYC-driven
breast tumor models during tumor growth and early regression.
Cancers 2021, 13, 148 8 of 20
2.5. Using Bodipy FL c16 to Determine Drug Efficacy
We next demonstrated that Bodipy FL c16 imaging can be applied to study in vivo
efficacy of drugs that attenuate LCFA uptake. We tested whether perphenazine, a drug
previously shown to inhibit LCFA uptake [40,59], can reduce fatty acid uptake in 4T1
tumors, a highly metastatic triple-negative breast cancer cell line [39]. Perphenazine,
a United States Food and Drug Administration (FDA)-approved drug used to treat patients
with schizophrenia, binds to a subset of FATPs and reduces LCFA uptake in vitro and in
a yeast-based functional screen [40,59].
We first imaged Bodipy FL c16 uptake in vitro using a confocal microscope following a
2 h incubation with 80 µM perphenazine (Figure 5A) per standard protocols [40]. Bodipy FL
c16 uptake was significantly decreased in 4T1 cells treated with perphenazine (Figure 5B)
(p < 0.05). We also observed comparable results with two other cell lines from the same
family (Figure S3). To monitor fatty acid uptake following perphenazine treatment in vivo,
mammary window chambers were established, as previously described, over 4T1 tumors.
On the day of imaging, the mammary window coverslip was removed and 80 µM per-
phenazine was topically applied to the exposed tissue for 2 h [40]. Following treatment, the
window was rinsed with sterile phosphate-buffered saline (PBS), followed by our standard
Bodipy FL c16 imaging protocol. Representative Bodipy60 images of a 4T1 tumor with
and without perphenazine treatment are shown in Figure 5C. Short-term treatment with
perphenazine significantly decreased Bodipy60 in 4T1 tumors (Figure 5D) (p < 0.05). We
observed comparable results with in vivo non-tumorous mammary tissue treated with and
without perphenazine (Figure S4).
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2.6. Fatty Acid Uptake and Tumor Heterogeneity Increase with Metastatic Potential
Finally, because alterations in tumor metabolism can influence how aggressive a tumor
is [9,10], we applied our Bodipy FL c16 imaging technique to test whether intravital Bodipy
FL c16 imaging can distinguish between more and less aggressive tumors. The 4T1 tumor
family, consisting of 67NR, 4T07, and 4T1 cell lines that arose from the same TNBC parental
tumor [39], is known for the differing metastatic potential of each cell line [38]. The 4T1
tumor cells are considered the most aggressive because they have the highest rate of
metastases, with secondary nodules often forming in the lungs and liver. The 4T07 tumor
cells can mobilize from the primary tumor site but are only found in the blood, lymph
nodes, and sometimes the lung, where they often fail to proliferate. The 67NR tumor
cells are not detected in the blood, lymph nodes, or lungs [38,39]. Previous work has
demonstrated that 4T1 and 4T07 cells have increased oxidative phosphorylation compared
to 67NR cells as well as the 4T1 cells’ increased glycolytic flux compared to 67NR cells
observed in an in vitro setting [60].
Both in vitro studies on cell monolayers and in vivo studies on mammary tumors in
a window chamber model were performed here. Briefly, cell monolayers were incubated
with 1 µM Bodipy FL c16 for 30 min prior to being washed and imaged immediately with
a confocal microscope. Bodipy FL c16 uptake in 4T1 and 4T07 cell lines are significantly
higher than that in the 67NR cell line (Figure S3). This trend is observed in vivo, as
shown in Figure 6A. The 4T1, 4T07, and 67NR tumors were all grown to 5 × 5 mm in
the mammary fat pad of female BALB/c mice, which maintain a fully intact immune
system. Representative Bodipy60 images for each group are shown in Figure 6A. We also
leveraged the spatial information within the images to investigate how tumor heterogeneity
changes with metastatic potential. Local range images to represent heterogeneity, shown in
Figure 6B, were created by calculating the local range (difference between maximum pixel
intensity and minimum pixel intensity) for the nearest 1% of pixels for each respective
pixel in an image.
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Figure 6. Bodipy60 intensity and heterogeneity is increased in metastatic-prone tumors. (A) Representative Bodipy60
intensity images of 67NR, 4T07, and 4T1 tumors in vivo. (B) Representative local range Bodipy60 images of 67NR, 4T07,
and 4T1 tumors in vivo. Scale bar = 200 µm. (C) Bodipy60 fluorescence intensity vs. local range Bodipy60 for each pixel
(sample size: 4T1 = 6 mice, 4T07 = 5 mice, 67NR = 5 mice). Statistical differences in average fluorescence intensity and local
range between groups were determined using a KS test.
The local range values for each pixel were plotted against its corresponding Bodipy60
intensity value in Figure 6C. The Bodipy60 intensity is increased in 4T07-bearing mammary
window chambers compared to both 4T1- and 67NR-bearing windows, though only signif-
icant for 67NR (p < 0.05). We probed a recently published RNA-sequencing dataset and
found that 4T1 cells have higher Myc mRNA when compared with 67NR cells [61]. While
Slc27a3 mRNA expression followed the trend of Myc expression, it was not significantly
different between 67NR and 4T1 cells (Figure S5). These data show that the more metastatic
4T1 and 4T07 primary tumors have increased fatty acid uptake compared to non-metastatic
tumors. When looking at heterogeneity, both 4T1 and 4T07 tumors showed significantly
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increased local range relative to 67NR tumors (p < 0.05). 4T1 tumors also showed increased
heterogeneity compared to 4T07 tumors that trended towards significant (p = 0.057).
3. Discussion
Our and others’ prior work indicate evidence of fatty acid dependencies in certain
cancers [22,43,62–66]. However, there are surprisingly few technologies that can directly
compare tumor lipid uptake in vivo, especially at length scales that can fill the gap between
in vitro assays and whole-organ imaging. In the work presented here, we addressed this
shortcoming in the literature through the development and validation of a fluorescence-
based, longitudinal fatty acid uptake imaging approach in two distinct in vivo murine
models. With this approach, we found increased fatty acid uptake in MYC-high tumors and
tumors with high metastatic potential. Additionally, we demonstrate fatty acid inhibition
with a reported decrease in fluorescence signal following the addition of perphenazine,
a known fatty acid inhibitor. Finally, we demonstrate the utility of this imaging technique
to capture fatty acid uptake heterogeneity in tumors, finding that the spatial heterogeneity
of lipid metabolism is highest in the metastatic-prone 4T1 and 4T07 tumors compared to
67NR tumors, with the 4T1 tumors exhibiting the highest heterogeneity. Taken together,
this allows for spatial and temporal reporting of cancer cell fatty acid uptake in local tumor
microenvironments.
We tested our imaging approach in a MYC model, which has previously been shown
to take up fatty acids from the circulation, validating the ability of our method to quantify
fatty acid uptake in a regulated system. Bodipy FL c16 imaging, however, has the added
advantage of permitting dynamic temporal imaging as MYC-driven tumors form and
regress. The MTB-TOM model showcases two critically needed features for clinically
relevant studies of fatty acid uptake: (1) longitudinal metabolite tracking in a single animal
for intra-animal decreases in fatty acid uptake following oncogene downregulation, and
(2) providing a link between fatty acid uptake and tumor aggressiveness.
Longitudinal imaging of Bodipy FL c16 led to the finding that MYC-dependent tumors
have decreased fatty acid uptake following MYC downregulation, which serves as a proof
of concept for future testing of MYC-specific therapeutic interventions. This decreased
uptake is also correlated with a visible reduction in tumor size [50]. We link FATP3
expression with MYC expression. While our data suggest that treatment with inhibitors
of FATP3 or knocking down this LCFA carrier protein would drive anti-tumor effects
under the setting of MYC-high tumors, we did not directly test it here as it was beyond
the scope of the present study. Future studies can be carried out to test the role of FATP3
in breast cancer. Indeed, studying Bodipy FL c16 uptake in MYC-driven tumors serves as
an example of how potentially actionable targets can be identified when RNA-level and
protein-level studies accompany optical imaging.
Intravital Bodipy FL c16 imaging can also report on the activity of fatty-acid-uptake-
targeted therapies, such as perphenazine, both in vivo and in vitro. While we do not know
the exact mechanism, perphenazine likely targets the FATP family. FATP (1–6) have roles
in fatty acid uptake and/or activation in cells, so our group sought to image their effects on
Bodipy FL c16′s uptake kinetics [59]. Prior research in yeast demonstrated perphenazine’s
ability to block FATP2 [67]; however, there is likely some inhibitory effect on other FATP
receptors. Our data supports future studies on perphenazine, where our method could be
used to examine drug-dosing and minimal doses to target fatty acid uptake and oxidation
in cancer, in order to reduce side effects. Though only one drug is tested here, the platform
can be applied to a wide variety of fatty acid uptake or β oxidation inhibitors through
either topical or systemic administration.
Previous studies have implicated increases in both fatty acid uptake and β oxida-
tion in overall tumor aggressiveness and metastatic potential beyond MYC-inducible mod-
els [15,57,68–71]. The tumors of the 4T1 family of cell lines, which vary in metastatic potential
(4T1 > 4T07 > 67NR), were selected to assess whether our technique could associate differences
in fatty acid uptake across tumors of varying metastatic potential [39]. Bodipy FL c16 fluores-
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cence was indicative of metastatic potential (higher in 4T1 and 4T07 vs. 67NR). Through an
existing dataset, we show that Myc mRNA expression is higher in 4T1 cells in comparison
with 67NR cells. This is consistent with previous findings that breast cancer patients with
the highest Myc gene signature are most likely to have disease recurrence [72]. Aside from
MYC-driven tumors alone, fatty acid oxidation in TNBC and its respective metastasis have
recently been linked to the activation of the proto-oncogene tyrosine-protein kinase SRC [57].
SRC expression specifically has been shown to be elevated in both 4T1 and 4T07 tumors
compared to 67NR tumors, and the knockdown of Src significantly inhibited the metastatic
burden of 4T1 tumors [73,74]. The increased fatty acid uptake in all aggressive tumor lines
suggests a metabolic switch associated with the use of exogenous fatty acids in the spread of
metastatic disease. This idea is supported by previous studies implicating fatty acid uptake
and oxidation as a key promoter of tumor cell migration [70,75,76].
Although 4T1 and 4T07 tumors have comparable Bodipy FL c16 fluorescence intensi-
ties, which are significantly higher than that of 67NR tumors, 4T1 tumors showed a greater
degree of heterogeneity, measured by local range, compared to both 67NR and 4T07 tumors.
Along with increased fatty acid metabolism reportedly correlated with increased metastatic
and aggressive tumors, tumor metabolic heterogeneity has also been reported in the lit-
erature to correlate with increased tumor aggressiveness [75]. Previous work highlights
the presence of lipid spatial heterogeneity, specifically, and the importance of capturing
this metric to better phenotype the tumor metabolic landscape [76]. Further, increased
heterogeneity captured via texture analysis has previously been associated with increased
tumor grade and metastases [77,78]. Texture analysis has been extensively studied in
clinical imaging in computed tomography (CT), PET, and (magnetic resonance imaging)
MRI imaging and shows promise in improving diagnosis and tumor staging [79,80]. Here,
we show that texture analysis of fatty acid uptake used in conjunction with the magnitude
of the fluorescence intensity level can delineate highly metastatic (4T1) tumors from mildly
metastatic (4T07) and non-metastatic (67NR) tumors. Because TNBC is a molecularly
heterogeneous disease, imaging the tumor metabolic landscapes is vital to ensure a better
understanding of a tumor’s energetic phenotype [81]. Future studies can apply this method
to a broader group of tumor types that vary in metastatic potential to examine whether lipid
uptake levels and heterogeneity throughout the tumor could be used as a complementary
readout for reduced aggressiveness.
This work demonstrates that optical imaging of Bodipy FL c16 is important for lipid
metabolism research. These studies are paramount to the successful translation of targeted
metabolic therapies for TNBC and the plethora of other tumors that are dependent on fatty
acids [57,63,82]. The drug screening protocol demonstrated here could also be applied to
image the lung, liver, or brain through abdominal or cranial window chamber models,
respectively [83,84]. Tumors in each of these locations have reportedly shown a dysreg-
ulated lipid metabolism [82,85,86]. More invasive window chambers of non-superficial
organs, such as liver or lung windows, would require terminal imaging sessions; therefore,
only single time points could be captured without more advanced surgical techniques.
Additionally, the methodology developed here can be extended to other optical imaging
modalities such as in vivo imaging systems (IVIS) or fluorescence spectroscopy systems for
non-invasive monitoring of solid tumors. Collectively, this technique can provide a quanti-
tative measurement for fatty acid uptake across various disease and imaging models to
screen potential therapeutics.
In addition to the disease models used here, this technology can be used in can-
cer pharmacology research to quantify metabolic changes in human tumors following
therapies through the use of patient-derived xenograft (PDX) models and organoids for
prognostication and to inform future treatment regimens, as both have shown to reca-
pitulate metabolic features seen in patients [87,88]. In fact, we have previously shown
that exogenous fluorophores can be imaged using organoid models of human epidermal
growth factor receptor 2 (HER2)-driven breast cancer [89]. Our method could also be useful
for clinical applications, though the use of short-wavelength fluorescent indicators, such as
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Bodipy FL c16, would be limited to direct measurement of superficial lesions such as in
the oral cavity, cervix, or skin, or imaging of biopsies taken from deeper seeded tumors.
That being said, the methods showcased here can be adopted for a broader application
with imaging modalities such as nuclear medicine (18F-FTHA) [22].
Optical imaging is complementary to currently available metabolic imaging methods,
including positron emission tomography (PET) as well as magnetic resonance spectral
imaging (MRSI). Each of these imaging approaches measures key metabolic endpoints
by providing short-term uptake kinetics of labeled metabolites with differing tradeoffs.
PET imaging, though most prevalently used for imaging glucose uptake, can also image
fatty acids [22] and mitochondrial [90] metabolism, while MRSI can report on pyruvate
and lactate uptake [91]. Both PET and MRSI can capture large fields of view, allowing for
whole-organ imaging with relatively longer penetration depths than optical imaging, on
the order of centimeters; however, increased penetration depth comes at the expense of
decreasing resolution. Conversely, optical imaging can study similar metabolic pathways
and endpoints across smaller length scales, providing the capability to image in vitro cell
cultures or tumor window chambers at higher resolution, specifically on the order of
microns, allowing optical metabolic imaging to fill a gap between in vitro cell-level assays
and whole organ imaging.
We provide evidence supporting the use of fatty acid uptake with other validated
metabolic imaging techniques (TMRE) to indicate effects on fatty acid oxidation in these
tumors through the addition of mitochondrial membrane potential imaging [33]. These
results are consistent with our prior work [43]. MYC overexpression can reprogram tumor
metabolism in multiple ways, including uptake and utilization of multiple metabolites (e.g.,
LCFA, glucose, and glutamine [92]) that can contribute to increased oxidative phosphoryla-
tion. Through in vivo optical imaging, metabolic phenotyping of MYC-driven cancers is
feasible. In addition, fluorescence imaging can capture multiple endpoints through spectral
unmixing, as we have shown previously, where membrane potential and glucose uptake
can be reported in the same imaging session [93]. The ability to capture multiple endpoints
in vivo highlights the benefit of optical imaging as an important method for metabolically
phenotyping cancer.
4. Materials and Methods
4.1. Ethics Statement
All in vivo murine experiments were conducted according to the Duke University
Institutional Animal Care and Use Committee (IACUC) (Protocol A072-18-03). All mice
were housed in an on-site housing facility with ad libitum access to food and water with
standard light/dark cycles. Tumor volumes were measured using calipers and calculated
as Volume = (Length ×Width2)/2, where width represents the smallest axis and length the
longest axis.
4.2. MYC-Overexpressing Murine Model
Viably frozen MTB-TOM tumors, generated from MTB-TOM (MMTV-rtTA/TetO-
MYC) [37] (University of California, San Francisco, CA, USA), were divided into 1–2 mm
chunks, rinsed in Dulbecco’s Modified Eagle Medium DMEM (Gibco, Montgomery Count,
Maryland, USA) supplemented with 10 ng/mL doxycycline, 10 µm/mL insulin, and
50 µg/mL gentamycin, and transplanted into the 4th right mammary fat pad of 4-week
old Friend Virus B (FVB/N) mice (Taconic, Rensselaer, NY, USA). Mice were administered
2 mg/mL doxycycline (Research Products International, Mount Prospect, IL, USA) through
their drinking water, to maintain MYC overexpression and tumorigenesis. As tumors
reached ~300 mm3, mice were imaged, and doxycycline was removed to initiate oncogene
downregulation and tumor regression for 4 days prior to the second imaging session as
tumors shrunk by roughly 50% in size. Four FVB/N mice were used for Bodipy imaging,
while two FVB/N mice were used for TMRE imaging.
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4.3. T1 Murine Model
The 4T1 and 4T07 cells were acquired from the American Type Culture Collection, and
the 67NR cells were generously provided by Dr. Fred Miller (Karmanos Cancer Institute,
Detroit, MI, USA) through Dr. Inna Serganova and Dr. Jason Koucher (Memorial Sloan
Kettering Cancer Center, New York, NY, USA). Cell lines were passaged every 2 days
in Roswell Park Memorial Institute (RPMI)-1640 medium (L-glutamine) with 10% fetal
bovine serum (FBS) and 1% antibiotics (Penicillin-Streptomycin). For in vivo injection,
the abdomen of 6–8 week old female BALB/c mice (Charles River) was cleaned using
70% ethanol and the 4th right mammary gland was palpated and injected with 100µL
(~50,000 cells) of 4T1 (n = 6 mice), 4T07 (n = 5 mice), or 67NR (n = 5 mice) cells suspended
in sterile RPMI-1640 (Corning, Corning, NY, USA) with no FBS or antibiotics using a 27G
needle. Tumors were imaged at a volume of ~150 mm3.
4.4. RNA Sequencing
The differential expression data from RNA-sequencing on the MTB-TOM tumors and
4T1 and 67NR cell lines were downloaded from GEO (GSE130922 and GSE104765) [53,61].
Data is reported as Log2FC after DESeq2 analysis [94] in R software.
4.5. Western Blot
Tumor tissue samples were flash-frozen in liquid nitrogen, and protein was extracted
via a Dounce homogenizer in a cocktail of RIPA buffer (Thermo, Waltham, WA, USA)
and proteinase (Roche, San Francisco, CA, USA) supplemented with phosphatase (Roche)
inhibitor. Protein samples were resolved using 4–12% sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE) gels (Life Technologies, Carlsbad, CA, USA) and
transferred to nitrocellulose membranes (iBlot 2, Life Technologies). To probe for FATP3
(12943-1-AP, Proteintech, Rosemont, IL, USA, 1:1000) and c-MYC (MYC) (ab32072, Ab-
cam, Cambridge, MA, USA, 1:1000), membranes were first incubated in primary antibody
overnight on a 4 ◦C shaker, then incubated with horseradish peroxidase (HRP)-conjugated
secondary antibody. To probe for β-actin (actin), membranes were incubated for one
hour at room temperature in horseradish peroxidase (HRP)-conjugated antibody (sc-47778
HRP, Santa Cruz, 1:10,000). Signals were visualized with enhanced chemiluminescence
(ECL) (Bio-Rad, Hercules, CA, USA), and chemiluminescence was acquired via Bio-Rad
ChemiDoc XRS+. Unsaturated band intensities were quantified using Fiji software.
4.6. Murine Mammary Window Chamber Model
Using a previously established procedure, titanium window chambers with 12 mm
diameter, No. 2 glass coverslips, were surgically implanted over the 4th right mammary
gland of 8–12 week old female BALB/c (Charles River) [95].
4.7. Imaging Probes
For in vitro imaging, Bodipy FL c16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-
Indacene-3-Hexadecanoic Acid, Thermofisher) was diluted in sterile RPMI-1640 (Corning)
to a final concentration of 1 µM and incubated in each cell plate for 30 min. Next, cells were
washed and imaged immediately with a standard confocal microscope (Zeiss 780 Upright
confocal microscope at the Duke University Light Microscopy Core Facility). A total of
9 representative fields of view across 3 independent plates per cell line were imaged, and
each cell line was measured on at least two different days.
For in vivo administration, Bodipy FL c16 was diluted to a final concentration of 200 µM
in dimethyl sulfoxide (DMSO). This concentration was titrated to achieve a final tissue-level
concentration (42.1–749.9 nM for these studies, calculated from tissue-mimicking phantoms
(not shown)) below levels where self-quenching has been observed [96] and similar to in vitro
studies [34]. TMRE (Tetramethylrhodamine Ethyl Ester, Life Technologies/ThermoFisher) was
diluted to a final concentration of 75µM in sterile PBS according to our previously established
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protocols [93]. Both probes were delivered systemically via tail vein injection, and the total
volume of each injection was 100 µL.
4.8. Fluorescence Microscopy System and Metabolic Imaging
All mice were fasted for 4 h (water provided) prior to imaging to ensure a normal-
ized metabolic rate for each animal [97]. Following fasting, imaging began immediately.
The animal was anesthetized using isoflurane (1–1.5% v/v) in room air in an induction
chamber. The animal was transferred to a heated (to maintain core body temperature)
microscope stage where a background image (laser on) and dark image (laser off) were
acquired prior to probe administration to account for signals from sources other than the
fluorescence probes. Each animal received 100 µL of 200 µM Bodipy FL c16 in DMSO or
75 µM of TMRE in sterile PBS via tail vein injection and fluorescence images were acquired
for 80 min. An exposure time of 5 s was used for both Bodipy FL c16 and TMRE images.
To account for daily light source variation, all images were background subtracted, beam
shape corrected, and calibrated according to a Rhodamine B standard imaged at each
imaging session prior to image analysis. Each mouse was imaged only once. The only
exception is with our genetically engineered mouse (GEM) model to track changes in
metabolism on dox (MYC-on) compared to no dox (MYC-off), where each mouse was
imaged twice, four days apart.
Our previously reported microscope [93] was used to capture fluorescence for both of
our metabolic endpoints. For Bodipy FL c16 imaging, a 488 nm crystal laser (DL488–100-O,
Crystal laser, Reno, NV, USA) was used to excite the probe, followed by a 505 nm long-pass
dichroic mirror (DMLP505R, Thorlab, Newton, NJ, USA) to reject the excitation light in the
emission channel. Emission signal was collected using a liquid crystal tunable filter (LCTF)
(VariSpec VIS-7-35, PerkinElmer, Inc. Waltham, MA, USA, 7 nm bandwidth) programmed
to collect at 515 nm and a high-resolution dual-modal charge-coupled device (CCD) (ORCA-
Flash4.0, Hamamatsu, Japan). For TMRE imaging, a 555 nm crystal laser (CL555-100-O,
Crystal laser, Reno, NV, USA) was used to excite the probe, followed by a 573 nm long-pass
dichroic mirror (FF573-Di01-25 × 36, Semrock, Rochester, New York, NY, USA) to reject the
excitation light in the emission channel. Emission signal was collected using the previously
described LCTF (programmed to collect at 585 nm) and CCD. The spectral microscope
system was calibrated wavelength by wavelength using a standard lamp source (OL 220 M,
S/N: M-1048, Optronic Laboratories, USA).
This system uses a Nikon CFI E Plan Achromat 4× objective (NA = 0.1, Nikon Instru-
ments Inc., Melville, NY, USA) for all imaging. This creates a single frame field of view of
2.1 × 1.6 mm and a lateral resolution of 2.2 µm, as measured using a 1951 USAF resolution
target [93]. This microscope was controlled by a custom-designed LabVIEW software.
4.9. Fatty Acid Uptake Chemical Inhibition
For in vitro inhibition experiments with perphenazine, 4T1 cells were treated with
80 µM perphenazine (Sigma Aldrich, St. Louis, MO, USA) dissolved in sterile RPMI-
1640 (Corning) for 2 h prior to in vitro staining and imaging according to the methods
above. A total of 9 representative fields of view across 3 independent plates per condition
were imaged, and each condition was measured on at least two different days. To ensure
doxycycline does not interfere with Bodipy FL c16 uptake, 4T1 cells were treated with
10 ng/mL doxycycline dissolved in sterile RPMI-1640 (Corning, Corning, NY, USA) or PBS
for 2 h prior to staining and imaged according to the protocol described above. A total of
9 representative fields of view across 3 independent plates per condition were imaged.
Separate cohorts of 4T1-bearing (n = 3 mice) or non-tumor (n = 3 mice) animals also
received topical treatment with 80 µM perphenazine dissolved in sterile PBS. Following
isoflurane anesthesia, the mammary window chamber was removed and 100 µL of per-
phenazine was applied to the exposed tissue. Following 2 h of incubation, sterile PBS was
used to wash the window, the coverslip was returned to the tissue, and imaging began
immediately according to the methods above.
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4.10. Data Processing and Statistical Analysis
All post-processing and statistical analysis of Bodipy FL c16 fluorescent imaging was
performed using MATLAB (MathWorks, Natick, MA, USA). Prior to further analysis, each
image collected first underwent background and dark noise subtraction by removing the
average value of an image collected with the laser source off (dark noise) and removing the
average signal imaged prior to fluorescent probe injection (background). Additionally, due
to the non-uniformity of illumination of a Gaussian light-source, each image was divided
by an image of a uniform phantom to correct for the beam shape. Finally, each image was
calibrated using a Rhodamine B standard solution imaged during each imaging session.
These methods accounted for autofluorescence, non-uniform illumination, and day-to-day
system variations, respectively. The resulting images were used for all statistical compar-
isons and images displayed in this study. The average intensity values at each imaging time
point (0–80 min) were calculated to generate a time course kinetic curve. Comparisons of
these curves were performed using a two-way analysis of variance (ANOVA). Additionally,
comparison of average intensities using our summary parameter, Bodipy60, representing
the fluorescence that is present 60 min post-injection, was performed using a Wilcoxon
signed-rank test for paired time points in our MTB-TOM model and using a Wilcoxon
rank-sum test followed by a post hoc Bonferroni correction for multiple comparisons in our
4T1 family of cell lines due to the non-normal distribution of Bodipy60 data points. Finally,
local range images were quantified by calculating the local range of pixels representing
1% of the surrounding pixels for each respective pixel. Comparisons of all intensity and
heterogeneity pixels for each group were performed using a KS test due to the non-normal
distribution of pixels.
5. Conclusions
As the growing literature implicates fat as a key carbon source for many cancers, there
is a need for a validated method to non-invasively image fatty acid uptake in vivo. In breast
cancer alone, for example, exogenous fatty acid uptake and oxidation have been shown to
be increased in primary TNBC [92], following therapy resistance in Her2 breast cancer [18],
and in residual disease across breast cancer subtypes [19]. Pinpointing particular cancers
with alterations in lipid metabolism may provide clues for targeting oncogenic metabolism
in the clinic. We present a method for in vivo optical imaging of fatty acid uptake to
metabolically phenotype in vivo tumors within their microenvironment. This technique is
complementary to existing in vitro metabolic assays and in vivo PET and MRS imaging and
can be used to detect and inform on alterations of tumor metabolism in preclinical studies
and screen and validate potential therapy efficacy for translation to future clinical studies.
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